Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Change in Account Payables: 2020-2025

Historic Change in Account Payables for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to -$110,000.

  • Foghorn Therapeutics' Change in Account Payables rose 91.86% to -$110,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$239,000, marking a year-over-year increase of 92.15%. This contributed to the annual value of -$2.5 million for FY2024, which is 392.55% down from last year.
  • According to the latest figures from Q3 2025, Foghorn Therapeutics' Change in Account Payables is -$110,000, which was up 85.27% from -$747,000 recorded in Q2 2025.
  • Over the past 5 years, Foghorn Therapeutics' Change in Account Payables peaked at $1.7 million during Q1 2023, and registered a low of -$1.4 million during Q2 2022.
  • Its 3-year average for Change in Account Payables is -$200,182, with a median of -$236,000 in 2023.
  • Within the past 5 years, the most significant YoY rise in Foghorn Therapeutics' Change in Account Payables was 847.62% (2022), while the steepest drop was 390.10% (2022).
  • Quarterly analysis of 5 years shows Foghorn Therapeutics' Change in Account Payables stood at -$21,000 in 2021, then soared by 847.62% to $157,000 in 2022, then slumped by 250.32% to -$236,000 in 2023, then skyrocketed by 241.53% to $334,000 in 2024, then soared by 91.86% to -$110,000 in 2025.
  • Its Change in Account Payables stands at -$110,000 for Q3 2025, versus -$747,000 for Q2 2025 and $284,000 for Q1 2025.